Clinical Trial Update: Extension of Study ZPV-200 [Phase 2]

View source ↗

Summary

Extension of the Phase 2 study ZPV-200 for uterine fibroids has completed, as reported by sponsor Repros Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• ZPV-200 (investigational product)

Snippet

Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 2 | Status: COMPLETED